SDX-21

SDX-21 is a preclinical-stage topical drug candidate being developed by SynDermix AG, a Swiss biotechnology company. It is the lead candidate from the company's Noxogen Therapeutics platform, which focuses on proprietary formulations designed to release nitric oxide (NO) locally at the site of application. Nitric oxide is a potent signaling molecule known for its antimicrobial, vasodilatory, and anti-inflammatory properties. The development of SDX-21 involves a collaboration with King's College London, announced in July 2019, aimed at optimizing the formulation for effective local delivery. While specific therapeutic indications have not been publicly disclosed, the platform's mechanism of action suggests potential utility in treating skin infections, chronic wounds, or other dermatological conditions where enhanced local blood flow and pathogen clearance are beneficial.